PUBLIC COMPANY
saveEncoded Therapeutics Inc
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
- phase2A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
- phase2A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
- —Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies
🐶 Hiring Signal
News
- Alphabet’s GV is one of biotech’s most influential corporate investorsThe corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.biospace · 23d ago
- 5 biggest venture capital raises of Q3 2026Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked asset…biospace · 1mo ago
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useKaryopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…biopharma_dive · 2mo ago
- Frazier adds $1.1B+ to small and mid-sized biotech fundFrazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for…biospace · 2mo ago
- Encoded raises $275M series F for Dravet syndrome gene therapyEncoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial reductions in seizures.biospace · 2mo ago
- Encoded closes $275M Series F for Dravet syndrome drugEncoded Therapeutics has tacked on $275 million in new capital, closing a Series F round led by GV and an undisclosed healthcare investor. The precision genetic medicine biotech said Wednesday that…endpoints · 2mo ago
- GV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturingNeuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up its internal manufacturing capabilities.fiercebiotech · 2mo ago
- #ASGCT26: Encoded's gene therapy reduced seizures in Dravet syndromeA gene therapy designed by Encoded Therapeutics reduced seizures by 76% in children with Dravet syndrome, a severe neurodevelopmental disorder. The remarkable reduction was observed only in three p…endpoints · 6mo ago
- STAT+: Drug meant to make gene therapy safer may also make it less effectiveEncoded Therapeutics gives a heads-up to other gene therapy company about the trade-offs with a drug meant to improve safety.stat · 6mo ago
comments(0)
5-min edit window · permanent after that